AXLRx Eli Lilly intelligence — Immunology in United States: 2 reports covering Immunology in United States.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US: IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2, and the efficacy bar has moved from PASI 75 to PASI 90.